Citation
Sleiman Itani, J Gray, Claire Tomlin. "An ODE Model for the HER2/3-AKT Signaling Pathway in Cancers that Overexpress HER2". American Control Conference (ACC), 30, July, 2010.

Abstract
Targeted drug therapies have proven very useful as cancer treatments, but some still demonstrate very little antitumor activity in certain cancers. A class of tyrosine kinase inhibitors (TKIs) that are unexpectedly inefficient in some cancers are those that target the human epidermal growth factor receptor (HER) family. This paper proposes a mathematical model of the HER signaling pathway for the study and treatment of cancers that overexpress. The goals of this paper are threefold. The first is to introduce an ODE model that agrees with the existing data over large time intervals, and the second is to use this model to understand the effects of applying certain drugs to such cancers. We finally use this model to determine a “steering-based” treatment scheme for cancers that overexpress HER2.

Electronic downloads

• http://ieeexplore.ieee.org/iel5/5512481/5530425/05531034.pdf?arnumber=5531034

• HTML

  Sleiman Itani, J Gray, Claire Tomlin. <a
  href="http://chess.eecs.berkeley.edu/pubs/782.html"
  >An ODE Model for the HER2/3-AKT Signaling Pathway in
  Cancers that Overexpress HER2</a>, American Control
  Conference (ACC), 30, July, 2010.

• Plain text

  Sleiman Itani, J Gray, Claire Tomlin. "An ODE Model for
  the HER2/3-AKT Signaling Pathway in Cancers that Overexpress
  HER2". American Control Conference (ACC), 30, July,
  2010.

• BibTeX

  @inproceedings{ItaniGrayTomlin10_ODEModelForHER23AKTSignalingPathwayInCancersThatOverexpress,
      author = {Sleiman Itani and J Gray and Claire Tomlin},
      title = {An ODE Model for the HER2/3-AKT Signaling Pathway
                in Cancers that Overexpress HER2},
      booktitle = {American Control Conference (ACC)},
      day = {30},
      month = {July},
      year = {2010},
      abstract = {Targeted drug therapies have proven very useful as
                cancer treatments, but some still demonstrate very
                little antitumor activity in certain cancers. A
                class of tyrosine kinase inhibitors (TKIs) that
                are unexpectedly inefficient in some cancers are
                those that target the human epidermal growth
                factor receptor (HER) family. This paper proposes
                a mathematical model of the HER signaling pathway
                for the study and treatment of cancers that
                overexpress. The goals of this paper are
                threefold. The first is to introduce an ODE model
                that agrees with the existing data over large time
                intervals, and the second is to use this model to
                understand the effects of applying certain drugs
                to such cancers. We finally use this model to
                determine a �steering-based� treatment scheme
                for cancers that overexpress HER2.},
      URL = {http://chess.eecs.berkeley.edu/pubs/782.html}
  }
  

Posted by Christopher Brooks on 24 Nov 2010.
For additional information, see the Publications FAQ or contact webmaster at chess eecs berkeley edu.